SPS
ARCT icon

Susquehanna Portfolio Strategies’s Arcturus Therapeutics ARCT Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$497K Sell
64,396
-38,681
-38% -$282K 0.01% 762
2025
Q4 		$632K Buy
103,077
+7,163
+7% +$77.4K 0.01% 732
2025
Q3 		$1.77M Buy
95,914
+14,737
+18% +$237K 0.03% 539
2025
Q2 		$1.06M Buy
+81,177
New +$960K 0.02% 494

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Portfolio Strategies's ARCT Position: Q1 2026 in Review

Susquehanna Portfolio Strategies reduced its Arcturus Therapeutics (ARCT) stake by 38% in Q1 2026, selling an estimated $282K and leaving 64,396 shares worth $497K. The position accounts for 0.01% of the portfolio, ranked #762.

Susquehanna Portfolio Strategies first reported a position in ARCT in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.77M in Q3 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Susquehanna Portfolio Strategies held 64,396 shares of Arcturus Therapeutics worth $497K as of Q1 2026.
  • Susquehanna Portfolio Strategies sold 38,681 Arcturus Therapeutics shares in Q1 2026, an estimated $282K.
  • Arcturus Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #762 holding.
  • Susquehanna Portfolio Strategies first reported a position in Arcturus Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's Arcturus Therapeutics position peaked at $1.77M in Q3 2025.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.